A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases

@article{Lee2018APS,
  title={A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases},
  author={Choon Kin Lee and Sunny Hei Wong and Grace Chung Yan Lui and Whitney Tang and Lai S Tam and Margaret Ip and Esther Hiu Yee Hung and Minhu Chen and Justin Che-yuen Wu and Siew Chien Ng},
  journal={Journal of Crohn's and Colitis},
  year={2018},
  volume={12},
  pages={954–962}
}
Background Biologic therapies have revolutionised the treatment of immune-mediated diseases including inflammatory bowel disease [IBD] and rheumatological disorders. However, biologic treatments are associated with an increased risk of reactivation of latent tuberculosis. Data from regular monitoring for latent tuberculosis infection [LTBI] during biologic treatment are lacking. Methods Consecutive patients eligible for biologic therapies were screened for LTBI and prospectively followed up… Expand
Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors
TLDR
Positive IGRA conversion among IBD patients treated with vedolizumab and/or ustekinumab appears to occur somewhat frequently, but its clinical implications remain to be elucidated. Expand
Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA?
TLDR
It has been shown that anti-TNF-α treated patients have a 14-fold increased risk of tuberculosis (TB) infection/reactivation compared with healthy controls. Expand
Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy
TLDR
Tuberculosis still develops in patients treated with tumor necrosis factor (TNF)–inhibitors despite prior screening and treatment for latent tuberculosis infection (LTBI). Expand
Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America
TLDR
Treatment with anti-TNFα increased the risk of active TB in IBD patients from an endemic area in Latin America and the time from the beginning of the treatment to the active TB diagnosis suggests a new TB infection. Expand
Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment
TLDR
The findings do not support routine serial TB retesting in biologic-treated patients with rheumatic diseases in the absence of TB risk factors and develop conversion of at least 1 screening test during long-term biologic treatment. Expand
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease
TLDR
Diagnostic methods for latent tuberculosis infection, different scenarios in which screening is to be performed, strategies to reduce the risk of tuberculosis once biological treatment is initiated and chemoprophylaxis guidelines for latentculosis infection are reviewed, as well as the management of active tuberculosis during biological treatment. Expand
Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune‐mediated inflammatory diseases: A longitudinal population‐based analysis using claims data
TLDR
Adherence to the recommended practice of screening for tuberculosis before treating with biologic agents in patients with immune‐mediated inflammatory diseases (IMIDs) in Japan is identified. Expand
Useful message in choosing optimal biological agents for patients with autoimmune arthritis.
TLDR
The strengths and weaknesses of bDMARDs are summarized and specifically focus on their uses in patients with comorbid conditions or with specific medical conditions, such as pregnancy. Expand
Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease
TLDR
Conversion of IGRA test often occurred early during infliximab treatment for Crohn's disease, monitoring frequency of IGra should be appropriately enhanced in the early stage of treatment. Expand
Characterization of and advanced diagnostic methods for ocular tuberculosis and tuberculosis.
TLDR
The latest advanced diagnostic methods for active TB and latent TB as well as various known manifestations of OTB are reported, and important elements of diagnosis and treatment are reviewed. Expand
...
1
2
...

References

SHOWING 1-10 OF 49 REFERENCES
Performance of Interferon-gamma Release Assay for Tuberculosis Screening in Inflammatory Bowel Disease Patients
TLDR
IGRA results are negatively impacted by immunosuppressive therapy, and current guidelines suggesting TB screening before anti-tumor necrosis factor therapy may be inadequate in patients already on immunosppressive drugs are suggested. Expand
Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
TLDR
In the IBD population under study, incidence of TB infection associated with anti-TNF therapy is higher than that reported in controlled trials and occurs early after treatment initiation, suggesting that more effective screening strategies are needed. Expand
PTU-050 Addressing The Issue of Indeterminate Interferon Gamma Release Assays Prior to Biologic Therapy in Patients with Inflammatory Bowel Disease Patients
TLDR
Almost one third of IBD patients had an indeterminate IGRA result with half of those having a second ind determinate result, which supports risk stratification with more weight added to the risk than IGRA alone. Expand
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
TLDR
Strategies to treat latent TB infection that are tailored to the at-risk population can effectively and safely lessen the likelihood of active TB in patients treated with TNF antagonists. Expand
Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
TLDR
In patients receiving immunosuppressive agents, both IGRA conversions and reversions were observed, and Serial IGRA testing may not be needed in patients with a positive initial IGRA result showing high IFN-γ levels, because of high consistency in the test results. Expand
Performance of interferon‐gamma release assays in patients with inflammatory bowel disease: A systematic review and meta‐analysis
TLDR
While it remains difficult to determine superiority between the IGRAs and the TST, both are negatively affected by IST and it is imperative that all patients receive screening prior to anti‐TNF therapy. Expand
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
TLDR
Active tuberculosis may develop soon after the initiation of treatment with infliximab, and physicians should screen patients for latent tuberculosis infection or disease before prescribing the drug. Expand
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
TLDR
The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA. Expand
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
TLDR
New cases of ATB still occur in patients treated with all available TNF antagonists due to lack of compliance with recommendations to prevent reactivation of LTBI, and continuous evaluation of recommendations is required to improve clinical practice. Expand
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6-mercaptopurine (6-MP) andExpand
...
1
2
3
4
5
...